Nelson Advisors invited to Chair the QSTP × Merck FemTech Accelerator 'State of FemTech' session

FemTech is no longer a niche category within healthcare innovation. Conditions such as menopause, endometriosis, and PCOS are gaining increasing recognition as major health concerns and areas with significant unmet market demand. PCOS alone affects an estimated 6–13% of women of reproductive age globally.

At the same time, women’s health technologies spanning diagnostics, mental health, and preventative care are attracting growing attention from founders, investors, and healthcare systems worldwide. Yet despite increasing momentum, many startups continue to face the same challenge: how do you scale meaningful innovation into sustainable healthcare businesses?

This question sat at the center of a recent expert session hosted through the QSTP × Merck FemTech Accelerator, where founders, researchers, and ecosystem experts gathered to discuss the realities shaping today’s FemTech landscape. Led by Julie Pelta, Director of FemTech & MedTech at Nelson Advisors and Health & Life Sciences Assessor at Innovate UK, the session explored the opportunities, bottlenecks, and operational challenges defining the next phase of women’s health innovation.

One message emerged consistently throughout the discussion: innovation alone is not enough.

Source: https://qstp.qa/blog/the-state-of-femtech-scaling-beyond-the-hype/